Allegis Pharmac Patent-Cliff Exposure & CMS Drug Spending Portfolio

Allegis Pharmac (US): 8 reconciled FDA prescription therapies, $11.0M 2024 CMS Part D & Medicaid spend, and $915 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies8
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$11.0M
2024 Medicare Part D Spend$507K
2024 Medicaid Spend$10.5M
California HCAI SB 17 FilingsSpecialty launch notice ($915 intro WAC)